We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on wallstreetbets Subreddit Page by MostCapital5741. In ...

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

The stock market has recently witnessed significant movements among key players in the technology and healthcare sectors.

Eli Lilly’s stock has hit a 52-week low at $697.35, nosediving over 10% this past week, which has investors holding their ...

Shares of technology tumbled with Apple Inc. leading the charge lower. That decline came on the heels of President Donald ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.